Nanogen to Merge with French Dx Firm Elitech in Reverse Acquisition
 
Nanogen said last week that it has signed a merger agreement with Paris-based diagnostic firm the Elitech Group that is structured as a reverse acquisition of Nanogen by the privately held Elitech.
 
Under the terms of the agreement, Nanogen said that Elitech shareholders are expected to receive shares of Nanogen common stock valued at €66.5 million ($98.5 million).
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.